Sovaldi, Gilead’s oral inhibitor used to treat chronic hepatitis C, costs 58,980 yuan ($8,938) for a 12-week supply in China — which is only one-fifth of its current price in the U.S. market.
When Gilead’s drug was first launched in the U.S. in 2013, it cost a widely-criticized $84,000 per 12-week course, which equates to $1,000 per pill. However, with increased competition and pressure from payers, Sovaldi’s average price has decreased significantly to roughly $44,700 per course, according to the report.
The biopharmaceutical company has a history of cutting the price of Sovaldi when launching the drug in regions outside the U.S. For example, to sell in India, Gilead slashed the price from $1,000 per pill to roughly $4 per pill.
Gilead remains under pressure to export Sovaldi as sales of the hepatitis C drug have stagnated in the U.S., according to the report.
More articles on supply chain:
6 must-reads for supply chain leaders this week
Roche sues Pfizer to prevent a biosimilar from entering US market
4 ways the FDA is addressing the saline bag shortage
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
